ClinicalTrials.gg
CompletedNCT03098550Updated Jul 23, 2021Results posted

A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread

A Phase 1/2 interventional study of Nivolumab and Daratumumab in Advanced Cancer, sponsored by Bristol-Myers Squibb. Completed at 20 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-23.

Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
105
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 44 under way, 6 of them phase 3. Nivolumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
39th of 120
105 · median 66
Started
2017
with 23 others
Phase 1/2
12 of 120
2 open now
Registered
42nd of 120
by date
Lead sponsor
28 of 120
Bristol-Myers Squibb

Among the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, this one is the 39th largest by enrollment, is one of 24 that started in 2017, is one of 12 in phase 1/2, and was the 42nd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

22 of the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether a combination of Nivolumab and Daratumumab is safe and effective when treating Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, that have advanced or have spread.

03

Conditions studied

  • Advanced Cancer

Keywords

  • Non-small cell lung cancer (NSCLC)
  • Triple Negative Breast Cancer (TNBC)
  • Pancreatic Cancer (PAC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

  • Patients with or advanced solid tumors
  • Women with or cytologically confirmed triple negative breast carcinoma
  • Participants with histologically or cytologically confirmed pancreatic adenocarcinoma
  • Participants with histologically or cytologically confirmed Non Small Cell Lung Cancer (NSCLC)

Exclusion criteria

Exclusion Criteria:

  • Active or .
  • Any serious or uncontrolled medical disorder
  • Prior active within the previous 3 years

Other protocol defined inclusion/exclusion criteria could apply

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
105 participants (actual)

Study arms

  • Experimental
    Immunotherapy Combination

    TNBC and PAC participants who are deriving clinical benefit will continue to be treated with the nivolumab plus daratumumab combination therapy

    Biological: Nivolumab · Biological: Daratumumab

  • Experimental
    Nivolumab Monotherapy

    NSCLC patients who are deriving clinical benefit will be treated with nivolumab monotherapy

    Biological: Nivolumab

Interventions

  • BiologicalNivolumab

    Specified dose on specified days

  • BiologicalDaratumumab

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs)

    Number of participants with any grade of adverse events (AEs) graded by Common Terminology Criteria for Adverse Events (CTCAE v4.0) to determine the safety and tolerability of Nivolumab and Daratumumab

    Time frame: From first dose to 30 days post last dose (up to 34 months)

  2. Number of Participants With Serious Adverse Events (SAEs)

    Number of participants with any grade of serious adverse events (SAEs) graded by Common Terminology Criteria for Adverse Events (CTCAE v4.0) to determine the safety and tolerability of Nivolumab and Daratumumab

    Time frame: From first dose to 30 days post last dose (up to 34 months)

  3. Number of Participants With Laboratory Abnormalities in Specific Liver Tests

    Number of participants with laboratory abnormalities in specific liver tests based on US conventional units to determine the safety and tolerability of Nivolumab and Daratumumab. The number of participants with the following laboratory abnormalities from on-treatment evaluations will be summarized: * ALT or AST \> 3 x ULN, \> 5 x ULN, \> 10 x ULN and \> 20 x ULN * Total bilirubin \> 2 x ULN * ALP \> 1.5 x ULN * Concurrent (within 1 day) ALT or AST \> 3 x ULN and total bilirubin \> 1.5 x ULN * Concurrent (within 30 days) ALT or AST \> 3 x ULN and total bilirubin \> 1.5 x ULN * Concurrent (within 1 day) ALT or AST \> 3 x ULN and total bilirubin \> 2 x ULN * Concurrent (within 30 days) ALT or AST \> 3 x ULN and total bilirubin \> 2 x ULN

    Time frame: From first dose to 30 days post last dose (up to 34 months)

  4. Number of Participants With Laboratory Abnormalities in Specific Thyroid Tests

    Number of participants with laboratory abnormalities in specific thyroid tests based on US conventional units to determine the safety and tolerability of Nivolumab and Daratumumab. The number of subjects with the following laboratory abnormalities from on-treatment evaluations will be summarized: * TSH value \> ULN and * with baseline TSH value \<= ULN * with at least one FT3/FT4 test value \< LLN within 2-week window after the abnormal TSH test * with all FT3/FT4 test values \>= LLN within 2-week window after the abnormal TSH test * with FT3/FT4 missing within 2-week window after the abnormal TSH test. * TSH \< LLN and * with baseline TSH value \>= LLN * with at least one FT3/FT4 test value \> ULN within 2-week window after the abnormal TSH test * with all FT3/FT4 test values \<= ULN within 2-week window after the abnormal TSH test * with FT3/FT4 missing within 2-week window after the abnormal TSH test

    Time frame: From first dose to 30 days post last dose (up to 34 months)

  5. Number of Participants With Laboratory Results of Worst CTC Grade

    Number of participants with laboratory test results of worst (CTC v4.0) grades 0-4 to determine the safety and tolerability of Nivolumab and Daratumumab

    Time frame: From first dose to 30 days post last dose (up to 34 months)

Secondary outcomes

  1. Objective Response Rate (ORR)

    Objective response rate (ORR) is defined as the percentage of treated participants who achieve a best response of complete response (CR) or partial response (PR) based on investigator assessments (using RECIST v1.1 criteria)

    Time frame: Up to 36 months

  2. Duration of Response (DOR)

    Duration of response (DOR) is defined as the time between the date of first documented response (Complete response or partial response) to the date of the first documented tumor progression as determined by Investigator (per RECIST v1.1 criteria), or death due to any cause, whichever occurs first

    Time frame: Up to 36 months

  3. Best Overall Response (BOR)

    Best overall response (BOR) is defined as the best response, as determined by Investigator, recorded between the date of first dose and the date of objectively documented progression per RECIST v1.1 criteria or the date of subsequent therapy, whichever occurs first.

    Time frame: Up to 36 months

  4. Progression Free Survival (PFS)

    Progression Free Survival (PFS) is defined as the time between the date of treatment start day and the date of first documented tumor progression, based on Investigator assessments (per RECIST v1.1 criteria), or death due to any cause, whichever occurs first.

    Time frame: Up to 36 months

  5. Nivolumab Serum Concentrations

    Pharmacokinetics (PK) assessed using serum concentration data for Nivolumab

    Time frame: From day 1 to follow-up 2 (up to 36 months)

  6. Daratumumab Serum Concentrations

    Pharmacokinetics (PK) assessed using serum concentration data for Daratumumab

    Time frame: From day 1 to follow-up 2 (up to 36 months)

  7. Percentage of Participants Anti Drug Antibody (ADA) by Positivity

    Percentage of participants Anti Drug Antibody (ADA) to assess immunogenicity by ADA positive status and ADA negative status, relative to baseline. ADA positive is a participant with at least one ADA-positive sample relative to baseline (ADA negative at baseline or ADA titer to be at least 4-fold or greater (\>=) than baseline positive titer) at any time after initiation of treatment. ADA Negative is a participant with no ADA-positive sample after initiation of treatment

    Time frame: Up to 36 months

07

Results

Posted Jul 23, 2021

Participant flow

Participant flow — Overall Study
MilestoneNivolumab + Daratumumab (TNBC)Nivolumab + Daratumumab (NSCLC)Nivolumab + Daratumumab (PAC)
Started412143
Completed010
Not completed412043
Withdrew: Disease progression301941
Withdrew: Study drug toxicity210
Withdrew: Death100
Withdrew: Adverse event unrelated to study drug601
Withdrew: Administrative reason by sponsor001
Withdrew: Other reasons200

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs)

Number of participants with any grade of adverse events (AEs) graded by Common Terminology Criteria for Adverse Events (CTCAE v4.0) to determine the safety and tolerability of Nivolumab and Daratumumab

Time frame:
From first dose to 30 days post last dose (up to 34 months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsNivolumab + Daratumumab (TNBC)Nivolumab + Daratumumab (NSCLC)Nivolumab + Daratumumab (PAC)
Number of Participants With Adverse Events (AEs)412142
PrimaryNumber of Participants With Serious Adverse Events (SAEs)

Number of participants with any grade of serious adverse events (SAEs) graded by Common Terminology Criteria for Adverse Events (CTCAE v4.0) to determine the safety and tolerability of Nivolumab and Daratumumab

Time frame:
From first dose to 30 days post last dose (up to 34 months)
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs)
ParticipantsNivolumab + Daratumumab (TNBC)Nivolumab + Daratumumab (NSCLC)Nivolumab + Daratumumab (PAC)
Number of Participants With Serious Adverse Events (SAEs)291429
PrimaryNumber of Participants With Laboratory Abnormalities in Specific Liver Tests

Number of participants with laboratory abnormalities in specific liver tests based on US conventional units to determine the safety and tolerability of Nivolumab and Daratumumab. The number of participants with the following laboratory abnormalities from on-treatment evaluations will be summarized: * ALT or AST \> 3 x ULN, \> 5 x ULN, \> 10 x ULN and \> 20 x ULN * Total bilirubin \> 2 x ULN * ALP \> 1.5 x ULN * Concurrent (within 1 day) ALT or AST \> 3 x ULN and total bilirubin \> 1.5 x ULN * Concurrent (within 30 days) ALT or AST \> 3 x ULN and total bilirubin \> 1.5 x ULN * Concurrent (within 1 day) ALT or AST \> 3 x ULN and total bilirubin \> 2 x ULN * Concurrent (within 30 days) ALT or AST \> 3 x ULN and total bilirubin \> 2 x ULN

Time frame:
From first dose to 30 days post last dose (up to 34 months)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities in Specific Liver Tests
ParticipantsNivolumab + Daratumumab (TNBC)Nivolumab + Daratumumab (NSCLC)Nivolumab + Daratumumab (PAC)
ALT OR AST > 3XULN6210
ALT OR AST > 5XULN526
ALT OR AST > 10XULN213
ALT OR AST > 20XULN000
TOTAL BILIRUBIN > 2XULN118
ALP > 1.5XULN10534
CONCURRENT ALT OR AST ELEVATION > 3XULN WITH TOTAL BILIRUBIN > 1.5XULN WITHIN ONE DAY115
CONCURRENT ALT OR AST ELEVATION > 3XULN WITH TOTAL BILIRUBIN > 1.5XULN WITHIN 30 DAYS115
CONCURRENT ALT OR AST ELEVATION > 3XULN WITH TOTAL BILIRUBIN > 2XULN WITHIN ONE DAY115
CONCURRENT ALT OR AST ELEVATION > 3XULN WITH TOTAL BILIRUBIN > 2XULN WITHIN 30 DAYS115
PrimaryNumber of Participants With Laboratory Abnormalities in Specific Thyroid Tests

Number of participants with laboratory abnormalities in specific thyroid tests based on US conventional units to determine the safety and tolerability of Nivolumab and Daratumumab. The number of subjects with the following laboratory abnormalities from on-treatment evaluations will be summarized: * TSH value \> ULN and * with baseline TSH value \<= ULN * with at least one FT3/FT4 test value \< LLN within 2-week window after the abnormal TSH test * with all FT3/FT4 test values \>= LLN within 2-week window after the abnormal TSH test * with FT3/FT4 missing within 2-week window after the abnormal TSH test. * TSH \< LLN and * with baseline TSH value \>= LLN * with at least one FT3/FT4 test value \> ULN within 2-week window after the abnormal TSH test * with all FT3/FT4 test values \<= ULN within 2-week window after the abnormal TSH test * with FT3/FT4 missing within 2-week window after the abnormal TSH test

Time frame:
From first dose to 30 days post last dose (up to 34 months)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities in Specific Thyroid Tests
ParticipantsNivolumab + Daratumumab (TNBC)Nivolumab + Daratumumab (NSCLC)Nivolumab + Daratumumab (PAC)
TSH > ULN434
TSH > ULN WITH TSH <= ULN AT BASELINE432
TSH > ULN WITH AT LEAST ONE FT3/FT4 TEST VALUE < LLN113
TSH > ULN WITH ALL OTHER FT3/FT4 TEST VALUES >= LLN220
TSH > ULN WITH FT3/FT4 TEST MISSING101
TSH < LLN122
TSH < LLN WITH TSH >= LLN AT BASELINE121
TSH < LLN WITH AT LEAST ONE FT3/FT4 TEST VALUE > ULN100
TSH < LLN WITH ALL OTHER FT3/FT4 TEST VALUES <= ULN021
TSH < LLN WITH FT3/FT4 TEST MISSING001
SecondaryObjective Response Rate (ORR)

Objective response rate (ORR) is defined as the percentage of treated participants who achieve a best response of complete response (CR) or partial response (PR) based on investigator assessments (using RECIST v1.1 criteria)

Time frame:
Up to 36 months
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR)
Percentage of ParticipantsNivolumab + Daratumumab (TNBC)Nivolumab + Daratumumab (NSCLC)Nivolumab + Daratumumab (PAC)
Objective Response Rate (ORR)4.9 (0.6 to 16.5)9.5 (1.2 to 30.4)0 (0.0 to 8.2)
SecondaryDuration of Response (DOR)

Duration of response (DOR) is defined as the time between the date of first documented response (Complete response or partial response) to the date of the first documented tumor progression as determined by Investigator (per RECIST v1.1 criteria), or death due to any cause, whichever occurs first

Time frame:
Up to 36 months
Reported as:
Median · Months
Duration of Response (DOR)
MonthsNivolumab + Daratumumab (TNBC)Nivolumab + Daratumumab (NSCLC)Nivolumab + Daratumumab (PAC)
Duration of Response (DOR)4.17 (NA to NA)9.40 (7.72 to 11.07)—
SecondaryBest Overall Response (BOR)

Best overall response (BOR) is defined as the best response, as determined by Investigator, recorded between the date of first dose and the date of objectively documented progression per RECIST v1.1 criteria or the date of subsequent therapy, whichever occurs first.

Time frame:
Up to 36 months
Reported as:
Count of participants · Participants
Best Overall Response (BOR)
ParticipantsNivolumab + Daratumumab (TNBC)Nivolumab + Daratumumab (NSCLC)Nivolumab + Daratumumab (PAC)
Complete Response (CR)000
Partial Response (PR)220
Stable Disease (SD)8109
Progressive Disease (PD)22931
Unable to Determine (UTD)903
SecondaryProgression Free Survival (PFS)

Progression Free Survival (PFS) is defined as the time between the date of treatment start day and the date of first documented tumor progression, based on Investigator assessments (per RECIST v1.1 criteria), or death due to any cause, whichever occurs first.

Time frame:
Up to 36 months
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsNivolumab + Daratumumab (TNBC)Nivolumab + Daratumumab (NSCLC)Nivolumab + Daratumumab (PAC)
Progression Free Survival (PFS)1.22 (1.15 to 1.41)4.85 (1.12 to 7.69)1.22 (1.15 to 1.38)
SecondaryNivolumab Serum Concentrations

Pharmacokinetics (PK) assessed using serum concentration data for Nivolumab

Time frame:
From day 1 to follow-up 2 (up to 36 months)
Reported as:
Geometric mean · µg/mL
Nivolumab Serum Concentrations
µg/mLNivolumab + Daratumumab (TNBC)Nivolumab (NSCLC)Nivolumab (PAC)
Cycle 3 Day 152.9 ± 34.843.5 ± 26.642.5 ± 29.7
Cycle 4 Day 187.0 ± 34.077.9 ± 37.664.3 ± 31.4
Cycle 7 Day 144.8 ± 32.8116.2 ± 23.883.3 ± NA
Cycle 11 Day 1—124.3 ± 46.5—
Follow-up 148.9 ± 44.071.6 ± 58.932.8 ± 48.6
Follow-up 223.5 ± 60.617.4 ± 96.16.3 ± 89.7
SecondaryDaratumumab Serum Concentrations

Pharmacokinetics (PK) assessed using serum concentration data for Daratumumab

Time frame:
From day 1 to follow-up 2 (up to 36 months)
Reported as:
Geometric mean · µg/mL
Daratumumab Serum Concentrations
µg/mLNivolumab + Daratumumab (TNBC)Daratumumab (NSCLC)Daratumumab (PAC)
Cycle 1 Day 1 (hour 8)334.1819 ± 28.1310.7272 ± 15.6277.6708 ± 28.4
Cycle 2 Day 1 (hour 0)332.9353 ± 29.6321.6084 ± 25.7275.1521 ± 35.9
Cycle 2 Day 1 (hour 4)735.2131 ± 36.9641.8146 ± 26.3569.8158 ± 27.4
Cycle 3 day 1629.9607 ± 19.8477.6488 ± 25.0473.0335 ± 23.8
Cycle 4 day 1559.8988 ± 31.0393.5442 ± 48.9406.9487 ± 28.2
Cycle 7 day 1294.8322 ± NA515.2495 ± 21.9229.0854 ± NA
Follow-up 1177.5615 ± 65.0157.5960 ± 62.2184.1510 ± 51.7
Follow-up 2134.0478 ± NA57.3349 ± NA8.4517 ± 158.4
SecondaryPercentage of Participants Anti Drug Antibody (ADA) by Positivity

Percentage of participants Anti Drug Antibody (ADA) to assess immunogenicity by ADA positive status and ADA negative status, relative to baseline. ADA positive is a participant with at least one ADA-positive sample relative to baseline (ADA negative at baseline or ADA titer to be at least 4-fold or greater (\>=) than baseline positive titer) at any time after initiation of treatment. ADA Negative is a participant with no ADA-positive sample after initiation of treatment

Time frame:
Up to 36 months
Reported as:
Number · Percentage of Participants
Percentage of Participants Anti Drug Antibody (ADA) by Positivity
Percentage of ParticipantsNivolumab + Daratumumab (TNBC)Nivolumab + Daratumumab (NSCLC)Nivolumab + Daratumumab (PAC)
Nivolumab Baseline ADA Positive0.006.30.00
Daratumumab Baseline ADA Positive0.005.60.00
Nivolumab ADA Positive0.000.000.00
Nivolumab ADA Negative100.0100.0100.0
Daratumumab ADA Positive0.000.000.00
Daratumumab ADA Negative100.0100.0100.0
PrimaryNumber of Participants With Laboratory Results of Worst CTC Grade

Number of participants with laboratory test results of worst (CTC v4.0) grades 0-4 to determine the safety and tolerability of Nivolumab and Daratumumab

Time frame:
From first dose to 30 days post last dose (up to 34 months)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Results of Worst CTC Grade
ParticipantsNivolumab + Daratumumab (TNBC)Nivolumab + Daratumumab (NSCLC)Nivolumab + Daratumumab (PAC)
Hemoglobin — Grade 01355
Hemoglobin — Grade 114923
Hemoglobin — Grade 27712
Hemoglobin — Grade 3503
Hemoglobin — Grade 4NANANA
Hemoglobin — Not Reported200
Platelet Count — Grade 0291624
Platelet Count — Grade 14418
Platelet Count — Grade 2000
Platelet Count — Grade 3111
Platelet Count — Grade 4500
Platelet Count — Not Reported200
Leukocytes — Grade 0271835
Leukocytes — Grade 1713
Leukocytes — Grade 2415
Leukocytes — Grade 3110
Leukocytes — Grade 4000
Leukocytes — Not Reported200
Alkaline Phosphatase — Grade 023136
Alkaline Phosphatase — Grade 17411
Alkaline Phosphatase — Grade 24113
Alkaline Phosphatase — Grade 32313
Alkaline Phosphatase — Grade 4000
Alkaline Phosphatase — Not Reported500
Aspartate Aminotransferase — Grade 0161620
Aspartate Aminotransferase — Grade 115313
Aspartate Aminotransferase — Grade 2215
Aspartate Aminotransferase — Grade 3415
Aspartate Aminotransferase — Grade 4000
Aspartate Aminotransferase — Not Reported400
Alanine Aminotransferase — Grade 0191219
Alanine Aminotransferase — Grade 115619
Alanine Aminotransferase — Grade 2101
Alanine Aminotransferase — Grade 3224
Alanine Aminotransferase — Grade 4000
Alanine Aminotransferase — Not Reported410
Bilirubin — Grade 0301830
Bilirubin — Grade 1514
Bilirubin — Grade 2013
Bilirubin — Grade 3116
Bilirubin — Grade 4000
Bilirubin — Not Reported500
Creatinine — Grade 0301538
Creatinine — Grade 1554
Creatinine — Grade 2110
Creatinine — Grade 3000
Creatinine — Grade 4000
Creatinine — Not Reported501
Phosphorous — Grade 0291533
Phosphorous — Grade 1002
Phosphorous — Grade 2454
Phosphorous — Grade 3213
Phosphorous — Grade 4000
Phosphorous — Not Reported601
Albumin — Grade 0151515
Albumin — Grade 113414
Albumin — Grade 26212
Albumin — Grade 3001
Albumin — Grade 4000
Albumin — Not Reported701
Amylase — Grade 09536
Amylase — Grade 1121
Amylase — Grade 2010
Amylase — Grade 3001
Amylase — Grade 4000
Amylase — Not Reported31135
Lipase — Grade 015631
Lipase — Grade 1115
Lipase — Grade 2011
Lipase — Grade 3003
Lipase — Grade 4001
Lipase — Not Reported25132
Hypernatremia — Grade 0352042
Hypernatremia — Grade 1100
Hypernatremia — Grade 2000
Hypernatremia — Grade 3000
Hypernatremia — Grade 4000
Hypernatremia — Not Reported511
Hyponatremia — Grade 0231220
Hyponatremia — Grade 112715
Hyponatremia — Grade 2000
Hyponatremia — Grade 3117
Hyponatremia — Grade 4000
Hyponatremia — Not Reported511
Hyperkalemia — Grade 0301735
Hyperkalemia — Grade 1435
Hyperkalemia — Grade 2301
Hyperkalemia — Grade 3001
Hyperkalemia — Grade 4000
Hyperkalemia — Not Reported411
Hypokalemia — Grade 0331933
Hypokalemia — Grade 1416
Hypokalemia — Grade 2000
Hypokalemia — Grade 3003
Hypokalemia — Grade 4000
Hypokalemia — Not Reported411
Hypercalcemia — Grade 0331642
Hypercalcemia — Grade 1240
Hypercalcemia — Grade 2010
Hypercalcemia — Grade 3000
Hypercalcemia — Grade 4000
Hypercalcemia — Not Reported601
Hypocalcemia — Grade 0251415
Hypocalcemia — Grade 18721
Hypocalcemia — Grade 2206
Hypocalcemia — Grade 3000
Hypocalcemia — Grade 4000
Hypocalcemia — Not Reported601
Hypermagnesemia — Grade 0342140
Hypermagnesemia — Grade 1102
Hypermagnesemia — Grade 2000
Hypermagnesemia — Grade 3000
Hypermagnesemia — Grade 4000
Hypermagnesemia — Not Reported601
Hypomagnesemia — Grade 0331738
Hypomagnesemia — Grade 1244
Hypomagnesemia — Grade 2000
Hypomagnesemia — Grade 3000
Hypomagnesemia — Grade 4000
Hypomagnesemia — Not Reported601
Hyperglycemia — Grade 01017
Hyperglycemia — Grade 1946
Hyperglycemia — Grade 2011
Hyperglycemia — Grade 3001
Hyperglycemia — Grade 4000
Hyperglycemia — Not Reported221528
Hypoglycemia — Grade 019614
Hypoglycemia — Grade 1001
Hypoglycemia — Grade 2001
Hypoglycemia — Grade 3000
Hypoglycemia — Grade 4000
Hypoglycemia — Not Reported221527

Adverse events

Collected over From first dose to 100 days post last dose (up to 36 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nivolumab + Daratumumab (TNBC)29/41 (70.7%)36/41 (87.8%)40/41 (97.6%)
Nivolumab + Daratumumab (NSCLC)11/21 (52.4%)17/21 (81%)21/21 (100%)
Nivolumab + Daratumumab (PAC)36/43 (83.7%)36/43 (83.7%)41/43 (95.3%)
Most frequent serious events
Showing 10 of 85
Most frequent serious events
EventNivolumab + Daratumumab (TNBC)Nivolumab + Daratumumab (NSCLC)Nivolumab + Daratumumab (PAC)
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)22/418/2125/43
Pleural effusionRespiratory, thoracic and mediastinal disorders8/410/211/43
PneumoniaInfections and infestations1/412/210/43
Respiratory tract infectionInfections and infestations0/412/210/43
PyrexiaGeneral disorders2/411/214/43
Abdominal painGastrointestinal disorders0/410/213/43
AstheniaGeneral disorders2/410/211/43
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/410/212/43
Acute coronary syndromeCardiac disorders0/411/210/43
Pericardial effusionCardiac disorders0/411/210/43
Most frequent other events
Showing 10 of 92
Most frequent other events
EventNivolumab + Daratumumab (TNBC)Nivolumab + Daratumumab (NSCLC)Nivolumab + Daratumumab (PAC)
AstheniaGeneral disorders12/4112/2111/43
Infusion related reactionInjury, poisoning and procedural complications18/4111/2118/43
Abdominal painGastrointestinal disorders8/414/2119/43
CoughRespiratory, thoracic and mediastinal disorders18/415/214/43
ConstipationGastrointestinal disorders12/419/2113/43
DiarrhoeaGastrointestinal disorders9/419/2117/43
NauseaGastrointestinal disorders16/418/2118/43
Back painMusculoskeletal and connective tissue disorders8/418/213/43
PruritusSkin and subcutaneous tissue disorders4/418/212/43
Decreased appetiteMetabolism and nutrition disorders15/415/2114/43

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Nivolumab + Daratumumab (TNBC)Nivolumab + Daratumumab (NSCLC)Nivolumab + Daratumumab (PAC)Total
Mean55.1 ± 13.159.5 ± 8.561.9 ± 9.458.8 ± 11.2
Sex: Female, Male
Sex: Female, Male(Participants)Nivolumab + Daratumumab (TNBC)Nivolumab + Daratumumab (NSCLC)Nivolumab + Daratumumab (PAC)Total
Female4172068
Male0142337
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Nivolumab + Daratumumab (TNBC)Nivolumab + Daratumumab (NSCLC)Nivolumab + Daratumumab (PAC)Total
Hispanic or Latino1001
Not Hispanic or Latino2032144
Unknown or Not Reported20182260
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Nivolumab + Daratumumab (TNBC)Nivolumab + Daratumumab (NSCLC)Nivolumab + Daratumumab (PAC)Total
American Indian or Alaska Native0000
Asian2002
Native Hawaiian or Other Pacific Islander0000
Black or African American1001
White33213589
Other50813
08

Study locations

20 sites
  • Pacific Shores Medical Group
    Long Beach, California 90813, United States
  • University Of Colorado
    Aurora, Colorado 80045, United States
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • University Of Michigan
    Ann Arbor, Michigan 48109, United States
  • Providence Portland Medical Center
    Portland, Oregon 97213, United States
  • Local Institution
    St Leonards, New South Wales 2065, Australia
  • Local Institution
    Edmonton, T6G 1Z2, Canada
  • Local Institution
    Lyon Cedex 08, 69373, France
  • Local Institution
    Marseille Cedex 9, 13273, France
  • Centre Paul Strauss
    Strasbourg Cedex, 67085, France
  • Universitaetsklinikum Carl Gustav Carus
    Dresden, 01307, Germany
  • Medizinische Universitaetsklinik Freiburg
    Freiburg, 79106, Germany
  • Universitaetsklinik Heidelberg
    Heidelberg, 69120, Germany
  • Local Institution
    Milano, 20132, Italy
  • Istituto Nazionale Tumori Fondazione Pascale
    Napoli, 80131, Italy
  • Fundacion De Investigacion
    San Juan, 00927, Puerto Rico
  • Hospital Gral. Univ. Gregorio Maranon
    Madrid, 28007, Spain
  • Local Institution
    Majadahonda - Madrid, 28222, Spain
  • Klinik Fur Onkologie
    Basel, 4031, Switzerland
  • University Hospital of Lausanne
    Lausanne, 1011, Switzerland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2017 to primary completion in Jul 2020, 36 months.

Results were first posted in Jul 2021, 1 year after primary completion.

Of 309 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's 36 months is below that.

Counting every sponsor, half of 432 studies reached it within 63 months; a quarter within 42 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2017
First posted
Mar 31, 2017
StartActual
Jun 15, 2017
Primary completionActual
Jul 6, 2020
CompletionActual
Jul 6, 2020
Results first posted
Jul 23, 2021
Last update
Jul 23, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03098550
Responsible party
Sponsor
First posted
Mar 31, 2017
Start date
Jun 15, 2017
Primary completion
Jul 6, 2020
Completion
Jul 6, 2020
Results posted
Jul 23, 2021
Last update
Jul 23, 2021

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion